Published in J Anal Toxicol on May 15, 2012
Legal highs: staying on top of the flood of novel psychoactive substances. Ther Adv Psychopharmacol (2015) 1.01
Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration? Drug Alcohol Depend (2012) 0.86
Marijuana Legalization: Impact on Physicians and Public Health. Annu Rev Med (2015) 0.86
Cannabis withdrawal in chronic, frequent cannabis smokers during sustained abstinence within a closed residential environment. Am J Addict (2014) 0.84
Current knowledge on cannabinoids in oral fluid. Drug Test Anal (2013) 0.83
Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration. Anal Bioanal Chem (2013) 0.80
Smoked cannabis' psychomotor and neurocognitive effects in occasional and frequent smokers. J Anal Toxicol (2015) 0.80
Blood levels do not predict behavioral or physiological effects of Δ⁹-tetrahydrocannabinol in rhesus monkeys with different patterns of exposure. Drug Alcohol Depend (2014) 0.80
Establishing legal limits for driving under the influence of marijuana. Inj Epidemiol (2014) 0.77
Cannabis and tolerance: acute drug impairment as a function of cannabis use history. Sci Rep (2016) 0.76
Plasma Cannabinoid Pharmacokinetics After Controlled Smoking and Ad libitum Cannabis Smoking in Chronic Frequent Users. J Anal Toxicol (2015) 0.76
Controlled vaporized cannabis, with and without alcohol: subjective effects and oral fluid-blood cannabinoid relationships. Drug Test Anal (2015) 0.75
Fasting and exercise increase plasma cannabinoid levels in THC pre-treated rats: an examination of behavioural consequences. Psychopharmacology (Berl) (2014) 0.75
Adverse effects of cannabis. Lancet (1998) 4.58
Dose related risk of motor vehicle crashes after cannabis use. Drug Alcohol Depend (2004) 3.13
Potency trends of Δ9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci (2010) 2.56
High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology (2006) 2.41
Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol (1993) 2.31
Relationship between the pharmacokinetics and pharmacodynamics of procainamide. Clin Pharmacol Ther (1976) 2.08
Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology (Berl) (2002) 1.84
Cognition and motor control as a function of Delta9-THC concentration in serum and oral fluid: limits of impairment. Drug Alcohol Depend (2006) 1.65
Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol (2008) 1.60
Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology (2001) 1.53
Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther (1980) 1.43
Pharmacokinetic properties of delta9-tetrahydrocannabinol in serum and oral fluid. J Anal Toxicol (2007) 1.42
Detection of marijuana use by oral fluid and urine analysis following single-dose administration of smoked and oral marijuana. J Anal Toxicol (2001) 1.41
Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clin Chem (2009) 1.28
Reinforcing and subjective effects of oral delta 9-THC and smoked marijuana in humans. Psychopharmacology (Berl) (1992) 1.20
Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration. Clin Chem (2010) 1.19
Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. Clin Chem (2011) 1.18
Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci (2007) 1.14
Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol (1992) 1.08
Characterization of the absorption phase of marijuana smoking. Clin Pharmacol Ther (1992) 1.07
Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg Delta9-THC. J Anal Toxicol (2005) 1.05
Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem (2011) 1.03
Cardiovascular effects of intravenous delta-9-tetrahydrocannabinol: autonomic nervous mechanisms. Clin Pharmacol Ther (1979) 1.00
Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC). Psychopharmacology (Berl) (2008) 1.00
Visual search and urban driving under the influence of marijuana and alcohol. Hum Psychopharmacol (2001) 0.99
The relationship between performance on the standardised field sobriety tests, driving performance and the level of Delta9-tetrahydrocannabinol (THC) in blood. Forensic Sci Int (2005) 0.98
Methodological issues in pharmacokinetic-pharmacodynamic modelling. Clin Pharmacokinet (1998) 0.96
Metabolism of delta 9-tetrahydrocannabinol by cytochrome P450 isozymes purified from hepatic microsomes of monkeys. Life Sci (1995) 0.93
Temporal indication of cannabis use by means of THC glucuronide determination. Drug Test Anal (2009) 0.91
Alcohol and marijuana: comparative dose effect profiles in humans. Pharmacol Biochem Behav (1988) 0.90
Delta-9-tetrahydrocannabinol (THC) serum concentrations and pharmacological effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg THC. Psychopharmacology (Berl) (2008) 0.88
Relationship between plasma delta-9-tetrahydrocannabinol concentration and pharmacologic effects in man. Psychopharmacology (Berl) (1981) 0.84
The effects of tetrahydrocannabinol on the recognition of emotionally charged words: an analysis using event-related brain potentials. Neuropsychobiology (1998) 0.82
Marijuana effect and delta-9-tetrahydrocannabinol plasma level. Clin Pharmacol Ther (1984) 0.81
Relating blood concentrations of tetrahydrocannabinol and metabolites to pharmacologic effects and time of marijuana usage. Ther Drug Monit (1993) 0.80
Kinetic study of smoking marijuana. J Pharmacokinet Biopharm (1982) 0.77
Management of alcohol withdrawal delirium. An evidence-based practice guideline. Arch Intern Med (2004) 4.55
Why should addiction medicine be an attractive field for young physicians? Addiction (2008) 3.52
Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials. Addiction (2011) 3.42
Introduction to behavioral addictions. Am J Drug Alcohol Abuse (2010) 3.22
Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend (2003) 2.68
Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend (2005) 2.26
Use of a 'microecological technique' to study crime incidents around methadone maintenance treatment centers. Addiction (2012) 2.20
Developing limits for driving under cannabis. Addiction (2007) 2.09
Cannabis effects on driving skills. Clin Chem (2012) 2.04
Cannabis withdrawal among non-treatment-seeking adult cannabis users. Am J Addict (2006) 1.94
Oral fluid testing for drugs of abuse. Clin Chem (2009) 1.89
Guidelines for research on drugged driving. Addiction (2008) 1.87
Methadone maintenance and breastfeeding in the neonatal period. Pediatrics (2008) 1.86
The Fagerstrom Test for Nicotine Dependence and the Diagnostic Interview Schedule: do they diagnose the same smokers? Addict Behav (2002) 1.74
Cannabinoids in exhaled breath following controlled administration of smoked cannabis. Clin Chem (2013) 1.67
Validated gas chromatographic-negative ion chemical ionization mass spectrometric method for delta(9)-tetrahydrocannabinol in sweat patches. Clin Chem (2004) 1.66
Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. Clin Chem (2003) 1.66
Medicinal Δ(9) -tetrahydrocannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in Standard Field Sobriety Tests. Addiction (2012) 1.65
Cocaine craving and use during daily life. Psychopharmacology (Berl) (2009) 1.62
Acute nicotine differentially impacts anticipatory valence- and magnitude-related striatal activity. Biol Psychiatry (2012) 1.62
Nicotine enhances visuospatial attention by deactivating areas of the resting brain default network. J Neurosci (2007) 1.61
On-site test for cannabinoids in oral fluid. Clin Chem (2012) 1.57
Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry. J Chromatogr A (2010) 1.53
Urinary cannabinoid detection times after controlled oral administration of delta9-tetrahydrocannabinol to humans. Clin Chem (2003) 1.48
Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther (2004) 1.46
The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl) (2009) 1.42
Reliability and validity of a short form of the Marijuana Craving Questionnaire. Drug Alcohol Depend (2009) 1.42
Pharmacokinetic properties of delta9-tetrahydrocannabinol in serum and oral fluid. J Anal Toxicol (2007) 1.42
Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. Drug Alcohol Depend (2009) 1.40
Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers. Drug Alcohol Depend (2010) 1.39
Questions on conflict of interest. Am J Psychiatry (2010) 1.38
Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology (Berl) (2007) 1.32
Matrix effect in bio-analysis of illicit drugs with LC-MS/MS: influence of ionization type, sample preparation, and biofluid. J Am Soc Mass Spectrom (2003) 1.31
Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults. Ther Drug Monit (2008) 1.29
An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology (2006) 1.29
Oral fluid cannabinoids in chronic, daily Cannabis smokers during sustained, monitored abstinence. Clin Chem (2011) 1.29
Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws. Clin Chem (2013) 1.29
A factor analysis of the Fagerström Test for Nicotine Dependence (FTND). Nicotine Tob Res (2003) 1.28
Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clin Chem (2009) 1.28
Neonatal abstinence syndrome in methadone-exposed infants is altered by level of prenatal tobacco exposure. Drug Alcohol Depend (2004) 1.26
Just say "I don't": lack of concordance between teen report and biological measures of drug use. Pediatrics (2010) 1.26
Cognitive measures in long-term cannabis users. J Clin Pharmacol (2002) 1.23
Duration of detectable methamphetamine and amphetamine excretion in urine after controlled oral administration of methamphetamine to humans. Clin Chem (2002) 1.23
Prenatal methamphetamine exposure and neonatal neurobehavioral outcome in the USA and New Zealand. Neurotoxicol Teratol (2010) 1.22
Quitting among non-treatment-seeking marijuana users: reasons and changes in other substance use. Am J Addict (2006) 1.21
Intrauterine growth of infants exposed to prenatal methamphetamine: results from the infant development, environment, and lifestyle study. J Pediatr (2010) 1.21
Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users? Addiction (2009) 1.21
Effect of rate of administration on subjective and physiological effects of intravenous cocaine in humans. Drug Alcohol Depend (2005) 1.20
Prenatal and postnatal cocaine exposure predict teen cocaine use. Neurotoxicol Teratol (2010) 1.19
Disposition of cannabinoids in oral fluid after controlled around-the-clock oral THC administration. Clin Chem (2010) 1.19
Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. Clin Chem (2011) 1.18
Urinary pharmacokinetics of methamphetamine and its metabolite, amphetamine following controlled oral administration to humans. Ther Drug Monit (2004) 1.16
Identifying new cannabis use with urine creatinine-normalized THCCOOH concentrations and time intervals between specimen collections. J Anal Toxicol (2009) 1.16
Oral fluid as a diagnostic tool. Clin Chem Lab Med (2004) 1.15
Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. Clin Chem (2014) 1.15
Effects of dose and route of administration on pharmacokinetics of (+ or -)-3,4-methylenedioxymethamphetamine in the rat. Drug Metab Dispos (2009) 1.15
The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. Drug Alcohol Depend (2012) 1.14
Concentrations of methadone in breast milk and plasma in the immediate perinatal period. J Hum Lact (2007) 1.12
Urine testing for cocaine abuse: metabolic and excretion patterns following different routes of administration and methods for detection of false-negative results. J Anal Toxicol (2003) 1.11
Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem (2010) 1.11
Simultaneous GC-EI-MS determination of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9-tetrahydrocannabinol, and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis. J Anal Toxicol (2007) 1.11
Urinary elimination of 11-nor-9-carboxy-delta9-tetrahydrocannnabinol in cannabis users during continuously monitored abstinence. J Anal Toxicol (2008) 1.10
Identification of prenatal amphetamines exposure by maternal interview and meconium toxicology in the Infant Development, Environment and Lifestyle (IDEAL) study. Ther Drug Monit (2009) 1.10
Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers. J Anal Toxicol (2009) 1.09
Cannabinoid disposition in oral fluid after controlled smoked cannabis. Clin Chem (2012) 1.09
Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol (2011) 1.08
Comparison of cannabinoid pharmacokinetic properties in occasional and heavy users smoking a marijuana or placebo joint. J Anal Toxicol (2008) 1.08
Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids. Ther Drug Monit (2006) 1.07
State of the art treatments for cannabis dependence. Psychiatr Clin North Am (2012) 1.07
A mechanism for the inhibition of neural progenitor cell proliferation by cocaine. PLoS Med (2008) 1.07
The second-oldest state psychiatric hospital in the United States. Am J Psychiatry (2014) 1.06
Calorie restriction increases cigarette use in adult smokers. Psychopharmacology (Berl) (2004) 1.06
Intra- and intersubject whole blood/plasma cannabinoid ratios determined by 2-dimensional, electron impact GC-MS with cryofocusing. Clin Chem (2009) 1.05
A liquid chromatography tandem mass spectrometry method for the simultaneous quantification of 20 drugs of abuse and metabolites in human meconium. Anal Bioanal Chem (2009) 1.05
Brain mu-opioid receptor binding predicts treatment outcome in cocaine-abusing outpatients. Biol Psychiatry (2010) 1.05
Metabolic effects of chronic cannabis smoking. Diabetes Care (2013) 1.04
Pharmacological treatment of cannabis dependence. Curr Pharm Des (2011) 1.04
A validated method for the determination of nicotine, cotinine, trans-3'-hydroxycotinine, and norcotinine in human plasma using solid-phase extraction and liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry. J Mass Spectrom (2006) 1.04
Quantification of nicotine, cotinine, trans-3'-hydroxycotinine, nornicotine and norcotinine in human meconium by liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.03
Performance effects of nicotine during selective attention, divided attention, and simple stimulus detection: an fMRI study. Cereb Cortex (2008) 1.03
Cannabinoid disposition in oral fluid after controlled cannabis smoking in frequent and occasional smokers. Drug Test Anal (2014) 1.03
Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem (2011) 1.03
Prenatal methamphetamine exposure and childhood behavior problems at 3 and 5 years of age. Pediatrics (2012) 1.03
A test of the cognitive self-medication hypothesis of tobacco smoking in schizophrenia. Biol Psychiatry (2013) 1.03
Pharmacokinetic properties of delta9-tetrahydrocannabinol in oral fluid of occasional and chronic users. J Anal Toxicol (2010) 1.02
First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry. Clin Chem (2013) 1.01
Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. J Clin Psychopharmacol (2008) 1.01